Eugene Slaughter

Eugene Slaughter

Auto-generated profile, based on publicly available information

Eugene Slaughter

School of Medical Sciences, Faculty of Medicine and Health (R.D.H., J.W., C.M., L.S., D.H., E.S., X.W., L.N., L.C., A.L.F., M.L., S.L.), University of Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJessica A. Schults
Jessica A. Schults
PCPauline Calleja
Pauline Calleja
ESEugene Slaughter
Eugene Slaughter
RPRebecca S. Paterson
Rebecca S. Paterson
CRClaire M. Rickard
Claire M. Rickard
MCMarie Cooke
Marie Cooke
Objective: To understand healthcare worker and patient experience with peripheral intravenous catheter (PIVC) insertion in patients with difficult intravenous access (DIVA) including the use of ultrasound (US). Methods: Descriptive study using 1-on-1 semi-structured interviews conducted between August 2020 and January 2021. Purposeful sampling was used to recruit healthcare practitioners (HCPs) and patients with DIVA who had PIVC experience. Data were analysed using inductive thematic analysis. Interview data were than mapped to the implementation theory Behaviour Change Wheel to inform implementation strategies. Results: In total 78 interviews (13 patients; 65 HCPs) were completed with respondents from metropolitan (60%), regional (25%) and rural/remote (15%) settings across Australia. Thematic analysis revealed 4 major themes: i) Harmful patient experiences persist, with patient insights not leveraged to effect change; ii) ‘Escalation’ is just a word on the front lines; iii) Heightened risk of insertion failure without resources and training; and iv) Paving the way forward–‘measures need to be in place to prevent failed insertion attempts. Themes were mapped to the behaviour change wheel and implementation strategies developed, these included: staff education, e-health record for DIVA identification, DIVA standard of care and DIVA guidelines to support escalation and ultrasound use. Conclusion(s): DIVA patients continue to have poor healthcare experiences with PIVC insertion. There is poor standardisation of DIVA assessment, escalation, US use and clinician education across hospitals. Quality, safety, and education improvement opportunities exist to improve the patient with DIVA experience and prevent traumatic insertions. We identified a number of implementation strategies to support future ultrasound and DIVA pathway implementation.

24 October 2020 in Worldviews on Evidence-Based Nursing
Verified
Journal Article
Closed access
PDF file
ESEugene Slaughter
Eugene Slaughter
Kate KynochKate Kynoch
Kate Kynoch
MBMegan Brodribb
Megan Brodribb
SKSamantha J. Keogh
Samantha J. Keogh

16 January 2026 in Circulation Research
Verified
Journal Article
Open access
RHRobert D. Hume
Robert D. Hume
JWJessica Warwick
Jessica Warwick
WSWoo Jun Shim
Woo Jun Shim
CMCassandra Malecki
Cassandra Malecki
MLMengbo Li
Mengbo Li
SLSean Lal
Sean Lal
BACKGROUND: Myocardial infarction (MI) is a leading cause of death worldwide and can eliminate up to a third of the cardiomyocytes within the human heart. Although cardiomyocytes undergo mitosis during early development, most cardiomyocytes cease cell cycling soon after birth. In contrast, rodent MI models have shown that cardiomyocytes increase mitosis in response to ischemia; however, this has not been shown in humans. METHODS: Using a unique premortem post-MI human heart, immunostaining, bulk RNA sequencing, proteomics, metabolomics, single-nucleus RNA sequencing and a novel post-MI human biopsy method, we investigated human cardiomyocyte mitosis post-MI. RESULTS: We show that adult human cardiomyocytes exhibit increased mitosis and cytokinesis in response to ischemia. CONCLUSIONS: Future development of therapeutics to enhance this intrinsic mitotic potential could lead to new treatments that reverse heart failure via cardiac regeneration.